INOVIO Announces Positive Results from REVEAL 1, a Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-based HPV Immunotherapy for the Treatment of High-grade Precancerous Cervical Dysplasia Caused by HPV-16 and/or HPV-18

Author's Avatar
Mar 02, 2021
Article's Main Image

Trial achieved primary and secondary efficacy endpoints among all evaluable subjects in the Phase 3 multi-center, randomized, double-blind, placebo-controlled trial

VGX-3100 is the first DNA medicine to achieve efficacy endpoints in a Phase 3 clinical trial

INOVIO also continues to partner with QIAGEN to develop a pre-treatment predictive biomarker with the goal of identifying women expected to respond to VGX-3100

PR Newswire